Conlin, A.K., Seidman, A.D., Bach, A., Lake, D., Dickler, M., D’Andrea, G., Traina, T., Danso, M., Brufsky, A.M., Saleh, M., Clawson, A. and Hudis, C.A. (2010) Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel with Carboplatin and Trastuzumab as Firstline Therapy for Women with HER2-Overexpressing Metastatic Breast Cancer. Clinical Breast Cancer, 10, 281-287.
https://doi.org/10.3816/CBC.2010.n.036

has been cited by the following article:

• TITLE: Impressive Objective Response to Nab-Paclitaxel plus Trastuzumab as Fifth Line Therapy in an Elderly HER-2 Positive Breast Cancer Patient

  AUTHORS: Maria Rosaria Valerio, Chiara Ancona, Antonella Marchese, Vittorio Gebbia

  KEYWORDS: Nab-Paclitaxel, Trastuzumab, HER-2, Metastasis, Breast Cancer

  JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.11, November 16, 2017

  ABSTRACT: Background: Agent targeting HER-2 pathway plus chemotherapy has represented a major progress in the management of patients with breast cancer. However, the role of late-line treatment in heavily pretreated patients is still largely unclear. In the last decade, nab-paclitaxel has shown significant activity and good toxicity profile in metastatic breast cancer. Case Presentation: We report the case of a 76-year-old Caucasian woman with metastatic HER-2 positive ductal infiltrating breast carcinoma treated with a combination of weekly nab-paclitaxel and trastuzumab as fifth-line therapy. She had previously received first-line paclitaxel and trastuzumab, second-line vinorelbine and trastuzumab, third-line TDM1 and fourth-line oral capecitabine and lapatinib. Clinical and radiological staging showed progression at bone, skin and soft-tissue. The patient received weekly nab-paclitaxel plus trastuzumab. Massive objective response was clinically and PET documented which lasted 8 months. Tolerance to treatment was fairly good as well as cardiac safety. Conclusion: To the best of our knowledge, this is the first reported case of efficacy of nab-paclitaxel in combination with trastuzumab as fifth-line of treatment in a patient with metastatic HER-2 positive breast cancer.